Relay Therapeutics (RLAY) Cash from Financing Activities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Financing Activities data on file, last reported at $138.8 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $138.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $140.5 million (changed N/A YoY), and the FY2025 annual result was $1.6 million, down 99.41% from the prior year.
• Cash from Financing Activities advanced to $138.8 million in Q1 2026 per RLAY's latest filing, from $934000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $285.9 million in Q3 2022 and troughed at $17000.0 in Q3 2025.
• A 5-year average of $49.0 million and a median of $2.0 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 31592.35% in 2022, then sank 99.99% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $1.2 million in 2022, then soared by 1779.76% to $21.9 million in 2023, then slumped by 96.35% to $800000.0 in 2024, then rose by 16.75% to $934000.0 in 2025, then surged by 14758.89% to $138.8 million in 2026.
• Business Quant data shows RLAY's Cash from Financing Activities at $138.8 million in Q1 2026, $934000.0 in Q4 2025, and $17000.0 in Q3 2025.